Summary

The 7 major cystinuria markets reached a value of US$ 81.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 133.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The cystinuria market has been comprehensively analyzed in IMARC's new report titled "Cystinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cystinuria is a genetic disorder that affects the way the body processes certain amino acids, particularly cystine. It is characterized by the abnormal buildup of cystine in the urine, which can lead to the formation of stones in the bladder, kidney, and urinary tract. The main symptom of this ailment includes sharp pain in the lower back or side of the stomach. Individuals suffering from cystinuria may also experience blood in the urine (hematuria), infections or blockages of the urinary tract, nausea, vomiting, abdominal discomfort, etc. Recurrences of these indications on a regular basis may eventually cause kidney damage in patients. The diagnosis of the illness is typically made based on a person's reported symptoms, medical history, and urinalysis. An X-ray examination of the urinary tract through an intravenous pyelogram, which involves the application of dye in the bloodstream to detect the stones, is further recommended to confirm a diagnosis. A healthcare provider may also perform a sodium cyanide-nitroprusside test for a simple, rapid, and qualitative evaluation of cystine concentrations in the body.

The rising cases of an inheritable autosomal recessive genetic abnormality that affects cystine reabsorption in the proximal renal tubule are primarily driving the cystinuria market. In addition to this, the inflating utilization of alkalinizing agents, such as acetazolamide and potassium citrate, which work by increasing the pH of urine, thereby making cystine more soluble, is also augmenting the market growth. Moreover, the widespread adoption of extracorporeal shock wave lithotripsy to treat this disease owing to its numerous benefits, including a lower risk of complications, a fast recovery time, improved outcomes in patients, etc., is further creating a positive outlook for the market. Additionally, various key players are making extensive investments in research activities to launch novel genetic counseling techniques that provide guidance on diagnosis and treatment options. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the escalating usage of laser therapy, which involves the insertion of a flexible ureteroscope through the urethra to precisely allow the fragmentation of stones into tiny pieces that can be easily passed down the urinary tract, is expected to drive the cystinuria market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cystinuria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cystinuria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cystinuria market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cystinuria market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cystinuria market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cystinuria marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the cystinuria market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cystinuria market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cystinuria market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cystinuria across the seven major markets?
What is the number of prevalent cases (2018-2034) of cystinuria by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cystinuria by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of cystinuria by type across the seven major markets?
How many patients are diagnosed (2018-2034) with cystinuria across the seven major markets?
What is the size of the cystinuria patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cystinuria?
What will be the growth rate of patients across the seven major markets?

Cystinuria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cystinuria drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cystinuria market?
What are the key regulatory events related to the cystinuria market?
What is the structure of clinical trial landscape by status related to the cystinuria market?
What is the structure of clinical trial landscape by phase related to the cystinuria market?
What is the structure of clinical trial landscape by route of administration related to the cystinuria market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Cystinuria - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Cystinuria - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Cystinuria - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 Cystinuria - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Cystinuria - Unmet Needs

10 Cystinuria - Key Endpoints of Treatment

11 Cystinuria - Marketed Products
11.1 List of Cystinuria Marketed Drugs Across the Top 7 Markets
11.1.1 Thiola EC (Tiopronin) - Mission Pharmacal
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Cystinuria - Pipeline Drugs
12.1 List of Cystinuria Pipeline Drugs Across the Top 7 Markets
12.1.1 ADV7103 - Advicenne
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Cystinuria - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Cystinuria – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Cystinuria - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cystinuria - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cystinuria - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cystinuria - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cystinuria - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cystinuria - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cystinuria - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cystinuria - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cystinuria - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cystinuria - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cystinuria - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cystinuria - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cystinuria - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cystinuria - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cystinuria - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cystinuria - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cystinuria - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cystinuria - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cystinuria - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cystinuria - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cystinuria - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cystinuria - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cystinuria - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cystinuria - Access and Reimbursement Overview

16 Cystinuria - Recent Events and Inputs From Key Opinion Leaders

17 Cystinuria Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Cystinuria Market – Strategic Recommendations

19 Appendix